Jyoti Chaudhary, MD
Internal Medicine · Searcy, ARNPI 1912214453
Payments from drug & device makers
Across 252 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- GSK$683
- Novo Nordisk$574
- Sanofi-aventis U.S. LLC$461
- Pfizer$307
- UCB, Inc.$284
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,078100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 36 | $1,203 |
| GSK | 50 | $683 |
| Novo Nordisk | 32 | $574 |
| Sanofi-aventis U.S. LLC | 30 | $461 |
| Pfizer | 18 | $307 |
| UCB, Inc. | 5 | $284 |
| Novartis | 16 | $267 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $164 |
| AstraZeneca | 7 | $135 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Abbott | 6 | $118 |
| Mylan Specialty L.p. | 5 | $103 |
| AbbVie | 3 | $84 |
| Sequel Med Tech, LLC | 2 | $66 |
| Medtronic | 3 | $63 |
| Boehringer Ingelheim | 2 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 4 | $40 |
| Lilly USA, LLC | 3 | $40 |
| Exact Sciences | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Astellas Pharma US Inc | 2 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Seqirus USA Inc | 1 | $21 |
| Bayer | 1 | $21 |
| Viatris Specialty LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,099 in reported general payments places this provider in the 85th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 86 | $103,136 |
| OzempicSemaglutide | 79 | $92,687 |
| EliquisApixaban | 77 | $70,052 |
| JardianceEmpagliflozin | 52 | $52,600 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $22,784 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $21,311 |
| XareltoRivaroxaban | 18 | $14,846 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $11,812 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $5,773 |
| Atorvastatin Calcium | 425 | $3,888 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,842 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $3,343 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 20 | $3,276 |
| Potassium Chloride | 156 | $3,156 |
| Duloxetine Hcl | 125 | $2,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Humulin 70-30 | $40 | $106,412106 claims |
| Novo NordiskOzempic | $574 | $92,68779 claims |
| PfizerEliquis | $307 | $70,05277 claims |
| Boehringer IngelheimJardiance | $54 | $52,60052 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $683 | $26,12739 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $461 | $22,38529 claims |
| Johnson & JohnsonXarelto | $14 | $14,84618 claims |
| AbbVieSynthroid | $84 | $1,05215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Searcy
- David JohnsonSearcy$630K
- John HendersonSearcy$102K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- Kathleen GannonRogers$450K
- Alexander KaczenskiLittle Rock$305K
- David PyleJonesboro$93K
- Manisha SinghLittle Rock$71K
- Govinda LohaniN Little Rock$55K
- Srikanth VallurupalliLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.